Persistency of neutralizing antibodies depends on titer and interferon-beta preparation

Multiple Sclerosis Journal

Volumn 18, Issue 5, 2012, Pages 610-615

  Hegen, Harald ^a   Schleiser, Manuel ^a   Gneiss, Claudia ^a   Di Pauli, Franziska ^a   Ehling, Rainer ^a   Kuenz, Bettina ^a   Lutterotti, Andreas ^a   Berger, Thomas ^a   Deisenhammer, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Interferon beta; multiple sclerosis; neutralizing antibodies; persistency; titer

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; FOLLOW UP; HUMAN; IMMUNOASSAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PREDICTION; SENSITIVITY AND SPECIFICITY;

EID: 84860495711     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511426738     Document Type: Article

References (32)

1. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009 ; 23: 379-396
2. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998 ; 50: 1266-1272
3. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005 ; 65: 40-47
4. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 ; 73: 1485-1492
5. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001 ; 56: 1628-1636
6. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1996 ; 47: 889-894
7. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 ; 362: 1184-1191
8. Gneiss C, Reindl M, Lutterotti A, et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler. 2004 ; 10: 507-510
9. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005 ; 65: 33-39
10. Herndon RM, Rudick RA, Munschauer FE, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler. 2005 ; 11: 409-419
11. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005 ; 65: 48-55
12. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1999 ; 52: 1277-1279
13. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
14. Gneiss C, Tripp P, Reichartseder F, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler. 2006 ; 12: 731-737
15. Millonig A, Rudzki D, Holzl M, et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler. 2009 ; 15: 977-983
16. Gneiss C, Reindl M, Berger T, et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res. 2004 ; 24: 283-290
17. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods. 1999 ; 227: 121-135
18. Gneiss C, Tripp P, Ehling R, et al. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol. 2006 ; 174: 174-179
19. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999 ; 52: 1239-1243
20. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology. 2003 ; 60: 37-43
21. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 ; 10: 126-138
22. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 ; 370: 389-397
23. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004 ; 62: 719-725
24. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002 ; 359: 1453-1460
25. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002 ; 59: 1496-1506
26. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004 ; 62: 2031-2037
27. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol. 2004 ; 251: 305-309
28. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008 ; 70: 1119-1127
29. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology. 2002 ; 59: 1507-1517
30. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler. 2007 ; 13: 208-214
31. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler. 2008 ; 14: 212-218
32. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000 ; 48: 95-100